- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Cystic fibrosis
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Elexacaftor with Tezacaftor and with Ivacaftor, and Ivacaftor – March 2025
Elexacaftor with Tezacaftor and with Ivacaftor, and Ivacaftor; Pack containing 56 tablets Elexacaftor 100 mg with Tezacaftor 50 mg and with Ivacaftor 75 mg and 28 tablets Ivacaftor 150 mg, Pack containing 56 tablets Elexacaftor 50 mg with Tezacaftor 25 mg and with ivacaftor 37.5 mg and 28 tablets Ivacaftor 75 mg, Pack containing 28 sachets Elexacaftor 100 mg with Tezacaftor 50 mg and with Ivacaftor 75 mg and 28 sachets Ivacaftor 75 mg, Pack containing 28 sachets Elexacaftor 80 mg with Tezacaftor 40 mg and with Ivacaftor 60 mg and 28 sachets Ivacaftor 59.5 mg; Trikafta®
